SCHEMBL2474956

SCHEMBL2474956

CN[C@@H](Cc1c[nH]cn1)C(=O)OC1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 2/20 0.39
▸ EPHX1 P07099 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ NPR3 P17342 1/20 0.36
▸ NLRP3 Q96P20 1/20 0.35
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ MMP2 P08253 2/20 0.32
▸ MMP9 P14780 2/20 0.32
▸ ANPEP P15144 2/20 0.32
▸ CACNA1B Q00975 1/20 0.32
▸ LTA4H P09960 1/20 0.32
▸ LAP3 P28838 1/20 0.32
▸ NPEPPS P55786 1/20 0.32
▸ ERAP2 Q6P179 1/20 0.32
▸ ERAP1 Q9NZ08 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336615 0.87 CYP19A1 (0.34) CYP19A1EPHX1SMN1; SMN2NPR3NLRP3
Hydrochloric Acid SCHEMBL3342710 0.86 CYP19A1 (0.33) CYP19A1EPHX1SMN1; SMN2NPR3NLRP3
SCHEMBL28201376 0.83 CACNA1B (0.47) CACNA1B
SCHEMBL28201377 0.83 CACNA1B (0.47) CACNA1B
SCHEMBL7780238 0.81 CYP19A1 (0.39) CYP19A1EPHX1SMN1; SMN2NLRP3NPC1
SCHEMBL7780240 0.81 CYP19A1 (0.39) CYP19A1EPHX1SMN1; SMN2NLRP3NPC1
SCHEMBL28774335 0.81 — —
SCHEMBL2059164 0.81 HDAC6 (0.36) NLRP3RAB9AGAAALDH1A1HSD17B10
SCHEMBL12765185 0.81 HDAC6 (0.36) NLRP3RAB9AGAAALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL9876601 0.79 HDAC6 (0.35) NLRP3ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9511120-B2 Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ACE2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation PONTIFICA UNIVERSIDAD CATÓLICA DE CHILE (CL) 2016-12-06 — — US disclosed
US-9132164-B2 Pharmaceutical compositions comprising angiotensin-(1-9), derivatives thereof, or a vector expressing ACE2, useful for treating cardiovascular, pulmonary, cerebral, and/or renal remodeling PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2015-09-15 — — US disclosed
US-20150190472-A1 USE OF THE ANGIOTENSIN-(1-9) PEPTIDE OR DERIVATIVES THEREOF, USE OF VECTORS OVEREXPRESSING THE ACE2 ENZYME THAT PRODUCES ANGIOTENSIN-(1-9) FOR PREPARING MEDICAMENTS USEFUL FOR PREVENTING, REVERTING, INHIBITING AND/OR REDUCING HYPERTENSION AND/OR INDUCING VASODILATION PONTIFICA UNIVERSIDAD CATOLICA DE CHILE (CL) 2015-07-09 — — US disclosed
EP-2377544-B1 PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) 2014-10-22 — — EP disclosed
US-20120172301-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ANGIOTENSIN-(1-9), DERIVATIVES THEREOF, OR A VECTOR EXPRESSING ACE2, USEFUL FOR TREATING CARDIOVASCULAR, PULMONARY, CEREBRAL, AND/OR RENAL REMODELING PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2012-07-05 — — US disclosed
EP-2377544-A2 PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT Pontificia Universidad Católica De Chile (CL) 2011-10-19 — — EP disclosed
Send feedback